Abstract

Isotretinoin safety reminderThe Medicines and Healthcare Products regulatory Agency (MHRA) has reminded prescribers to monitor patients treated with the retinoid isotretinoin for depression and to warn patients and their families to be alert for symptoms and suicidal thoughts (Drug Safety Update 2914;8(5):A2). The MHRA warns that stopping isotretinoin may not be enough to relieve symptoms and further psychiatric or psychological evaluation may be needed.Isotretinoin, available as the brands Roaccutane and Rizuderm, is licensed for the treatment of severe acne resistant to systemic antibacterials and topical therapy.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call